How Is the Cancer Biopsy Market Evolving Amid Rising Cancer Cases Globally?
The global cancer biopsy market is witnessing transformative growth, fueled by rising cancer incidence, technological innovation, and the increasing adoption of minimally invasive diagnostic procedures.
In 2024, the cancer biopsy market size across the 7 major markets was valued at USD 28.70 billion, and it is projected to grow at a CAGR of 13.20%, reaching USD 99.16 billion by 2034.
With the global rise in cancer cases and growing awareness about early diagnosis, biopsies—both traditional and liquid—are becoming indispensable tools for accurate cancer detection, staging, and personalized treatment decisions.
Cancer Biopsy Market Overview
A cancer biopsy is a medical test that involves removing a small sample of tissue or fluid from the body to determine the presence of cancer cells. Biopsies remain the gold standard for cancer diagnosis and play a crucial role in precision medicine, where treatment decisions are tailored to individual genetic profiles.
Key Market Drivers:
- Rising prevalence of solid tumors and hematologic malignancies
- Increasing adoption of liquid biopsy technologies
- Advancements in genomic and proteomic testing
- Growing emphasis on early cancer screening programs
- Expansion of oncology diagnostic infrastructure in developing regions
Market Restraints:
- High cost of advanced biopsy instruments
- Limited access to cancer diagnostic services in low-income countries
- Risk of procedural complications and false negatives in tissue biopsies
Cancer Biopsy Market Size and Growth Forecast (2025–2034)
The market growth is propelled by the increasing incidence of cancer worldwide, coupled with the shift toward non-invasive and real-time diagnostic techniques.
Liquid biopsies, in particular, are expected to witness exponential adoption due to their efficiency, speed, and ability to detect circulating tumor DNA (ctDNA) and tumor-derived exosomes.
Market Highlights:
- 2024 Market Size: USD 28.70 billion
- 2034 Forecast: USD 99.16 billion
- CAGR (2025–2034): 13.20%
- Base Year: 2024
- Forecast Period: 2025–2034
Cancer Biopsy Market Segmentation
1. Market Breakup by Product and Services
a) Kits and Consumables:
The largest revenue-generating segment, driven by frequent use in diagnostic labs and hospitals. These include reagents, assay kits, and consumables used in sample collection and analysis.
b) Instruments:
Comprises advanced biopsy devices, imaging systems, and automated platforms that enable precision-based tissue sampling.
c) Services:
Includes diagnostic, analytical, and genomic profiling services offered by clinical laboratories and cancer research institutions.
2. Market Breakup by Type
a) Needle Biopsy:
The most commonly performed biopsy type used for breast, lung, and liver cancers. It offers minimal invasiveness and rapid results.
b) Skin Biopsies:
Used to diagnose melanoma and other skin cancers. The segment benefits from growing dermatological awareness and screening programs.
c) Bone Marrow Biopsies:
Critical in diagnosing blood-related cancers such as leukemia, lymphoma, and myeloma.
d) Liquid Biopsies:
The fastest-growing segment, leveraging biomarkers like ctDNA, CTCs, and exosomes for early detection and monitoring of metastatic cancers.
e) Other Biopsies:
Includes surgical and endoscopic biopsies for gastrointestinal and gynecological cancers.
Regional Analysis of the Cancer Biopsy Market
The Cancer Biopsy Market Forecast 2025–2034 covers seven major regions: United States, United Kingdom, Germany, France, Italy, Spain, and Japan.
North America (United States)
- Holds the largest market share due to high cancer prevalence, robust healthcare infrastructure, and adoption of liquid biopsy and genomic sequencing technologies.
- Strong presence of companies like Thermo Fisher Scientific, Illumina, and BD enhances market competitiveness.
Europe (Germany, France, Italy, Spain, United Kingdom)
- Europe remains a key diagnostic hub, supported by favorable reimbursement policies and clinical trial activities.
- Countries such as Germany and the UK lead in adopting molecular diagnostic platforms and AI-based pathology tools.
Asia-Pacific (Japan)
- The fastest-growing market, driven by government initiatives in cancer screening, aging populations, and increasing healthcare spending.
- Rising investment in liquid biopsy research and next-generation sequencing (NGS) technologies further boosts growth.
Technological Innovations Transforming the Cancer Biopsy Market
Innovation is at the heart of market expansion, with technologies like next-generation sequencing (NGS), artificial intelligence (AI), and digital pathology reshaping diagnostic precision.
Emerging Trends:
- AI-integrated biopsy analysis: Enables pattern recognition and accurate tissue classification.
- Liquid biopsy advancement: Offers real-time cancer detection with reduced invasiveness.
- 3D imaging-guided biopsy systems: Improve precision and safety during tissue extraction.
- Companion diagnostics integration: Helps identify biomarkers for targeted therapies.
Key Market Players
Prominent players in the global Cancer Biopsy Market are continuously investing in R&D, strategic partnerships, and technological expansion to maintain competitive advantage.
Leading Companies:
- QIAGEN
- Illumina, Inc.
- ANGLE plc
- BD (Becton, Dickinson and Company)
- Bio-Rad Laboratories Inc.
- Hologic, Inc.
- BIOCEPT, INC.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
Recent Developments:
- Illumina expanded its portfolio with NGS-based cancer panels for liquid biopsy testing.
- QIAGEN introduced new sample preparation kits designed for oncology research.
- ANGLE plc launched an FDA-approved liquid biopsy platform targeting metastatic cancers.
Cancer Biopsy Market Opportunities and Challenges
Opportunities:
- Expanding adoption of personalized medicine and genomic profiling
- Rising healthcare investments in cancer screening programs
- Growth of home-based and point-of-care biopsy testing solutions
Challenges:
- Regulatory hurdles for new biopsy devices and tests
- Variability in test results due to sample handling and operator skill
- High equipment costs in developing countries
Future Outlook and Market Forecast Insights
The Cancer Biopsy Market is set for strong growth as global cancer rates continue to rise. Increasing integration of AI-driven diagnostics, molecular profiling, and liquid biopsy testing will redefine cancer detection and monitoring.
By 2034, the market is expected to be largely shaped by:
- Digital pathology systems enabling cloud-based analysis
- Multi-cancer early detection (MCED) tests
- Automation in biopsy processing for efficiency and consistency
- Expanding applications of ctDNA testing in treatment monitoring
The focus on precision oncology—identifying the right treatment for the right patient—will remain a critical growth driver in the forecast period.
Access More Reports
Artificial Insemination Market
Amyotrophic Lateral Sclerosis Market
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
